Patent intelligence · US
US 12194078
Methods and compositions related to combined treatment with anti-inflammatories and synthetic nanocarriers comprising an immunosuppressant
Methods and compositions related to combined treatment with anti-inflammatories and synthetic nanocarriers comprising an immunosuppressant
Patent details — US 12194078
- Jurisdiction
- US
- Status
- granted
- Grant date
- Jan 14, 2025
- Expiration
- Jan 9, 2045
- Applicant
- Cartesian Therapeutics, Inc.
- Claims
- 19
- CPC classes
- A61K, A61K2300/00, A61K31/165, A61K31/192
Quick answer
US 12194078 (Methods and compositions related to combined treatment with anti-inflammatories and synthetic nanocarriers comprising an immunosuppressant) is held by Cartesian Therapeutics, Inc.. Status: granted. Granted Jan 14, 2025. Expires Jan 9, 2045 (19 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- Cartesian Therapeutics, Inc.
- Grant date
- Expiration
- Claims
- 19
- CPC classes
- A61K, A61K2300/00, A61K31/165, A61K31/192, A61K31/436, A61K31/445
More from Cartesian Therapeutics, Inc.
Related pharmaceutical patents in our USPTO index.
Frequently asked questions
What is US patent 12194078?
US 12194078 (Methods and compositions related to combined treatment with anti-inflammatories and synthetic nanocarriers comprising an immunosuppressant) is held by Cartesian Therapeutics, Inc.. Status: granted. Granted Jan 14, 2025. Expires Jan 9, 2045 (19 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 12194078?
Cartesian Therapeutics, Inc. is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 4 pharmaceutical patents for this assignee.
When does US 12194078 expire?
Our index shows an expiration date of Jan 9, 2045 (19 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.